Research graph
References from Adaptive design increased success but does not significantly accelerate confirmatory oncology trials. Local targets link to admitted publications; unresolved targets remain external evidence.
Adaptive designs in clinical trials: why use them, and how to run and report them
10.1186/s12916-018-1017-7 · 2018 · External reference
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
10.1002/sim.6472 · 2016 · External reference
Adaptive treatment assignment methods and clinical trials
10.2307/2529473 · 1977 · External reference
10.1016/b978-0-12-237301-5.50007-5
10.1016/b978-0-12-237301-5.50007-5 · 1975 · External reference
Allocation of patients to treatment in clinical trials
10.2307/2529944 · 1979 · External reference
A decade of progress in statistical methodology for clinical trials
10.1002/sim.4780101203 · 1991 · External reference
Issues in the use of adaptive clinical trial designs
10.1002/sim.2626 · 2006 · External reference
Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project
10.1186/s13063-016-1493-z · 2016 · External reference
Unresolved reference
2007 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
2025 · External reference
Dexamethasone in hospitalized patients with Covid-19
10.1056/nejmoa2021436 · 2021 · External reference
Adaptive designs in clinical trials: a systematic review-Part I
10.1186/s12874-024-02272-9 · 2024 · External reference
Adaptive design clinical trials: current status by disease and trial phase in various perspectives
10.12793/tcp.2023.31.e21 · 2023 · External reference
New clinical trial design in precision medicine: discovery, development and direction
10.1038/s41392-024-01760-0 · 2024 · External reference
Breast cancer epigenetics: current and evolving treatment
10.1007/s12282-024-01601-6 · 2024 · External reference
The BATTLE trial: personalizing therapy for lung cancer
10.1158/2159-8274.cd-10-0010 · 2011 · External reference
Adaptive randomization of neratinib in early breast cancer
10.1056/nejmoa1513750 · 2016 · External reference
Costs of drug development and research and development intensity in the US, 2000-2018
10.1001/jamanetworkopen.2024.15445 · 2024 · External reference
Factors associated with successful phase III trials for solid tumors: a systematic review
10.1016/j.conctc.2021.100855 · 2021 · External reference
Exploratory analysis of the factors associated with success rates of confirmatory randomized controlled trials in cancer drug development
10.1111/cts.12852 · 2021 · External reference
Food and drug administration approvals in phase 3 cancer clinical trials
10.1186/s12885-021-08457-5 · 2021 · External reference
Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea
10.1038/s41434-023-00437-7 · 2024 · External reference
Oncology accelerated approval confirmatory trials: when a failed trial is not a failed drug
10.1200/jco-24-01654 · 2024 · External reference
Adaptive designs for clinical trials
10.1056/nejmra1510061 · 2016 · External reference
Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov
10.1136/bmjopen-2017-018320 · 2018 · External reference
A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials
10.1186/s12874-023-02024-1 · 2023 · External reference
A systematic review of adaptive seamless clinical trials for Late-Phase Oncology Development
10.1007/s43441-024-00670-1 · 2024 · External reference
Adaptive designs undertaken in clinical research: a review of registered clinical trials
10.1186/s13063-016-1273-9 · 2016 · External reference
Reporting quality was suboptimal in a systematic review of randomized controlled trials with adaptive designs
10.1016/j.jclinepi.2022.12.010 · 2023 · External reference
An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review
10.1371/journal.pone.0141104 · 2015 · External reference
Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings
10.1002/sim.4156 · 2011 · External reference
Economic evaluation of cost and time required for a platform trial vs conventional trials
10.1001/jamanetworkopen.2022.21140 · 2022 · External reference
Assessment of trends in the design, accrual, and completion of trials registered in ClinicalTrials.gov by sponsor type, 2000-2019
10.1001/jamanetworkopen.2020.14682 · 2020 · External reference
Cancer statistics, 2025
2025 · External reference
Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments
10.1016/s1470-2045(23)00182-1 · 2023 · External reference
Characteristics of clinical trials related to hip fractures and factors associated with completion
10.1186/s12891-022-05714-x · 2022 · External reference
Value of adaptive trials and surrogate endpoints for clinical decision-making in rare cancers
10.3389/fonc.2021.636561 · 2021 · External reference
Adaptive designs for trials aiming to optimise implementation strategies and the effect of an additional interim analysis: a simulation study
10.1186/s12874-025-02730-y · 2025 · External reference
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
10.1136/bmj.m115 · 2020 · External reference
Adaptive design methods in clinical trials - a review
10.1186/1750-1172-3-11 · 2008 · External reference
Benefits, challenges and obstacles of adaptive clinical trial designs
10.1186/1750-1172-6-79 · 2011 · External reference
Unresolved reference
2018 · External reference
Overall survival and quality-of-life superiority in modern Phase 3 oncology trials: a meta-epidemiological analysis
10.1001/jamaoncol.2025.1002 · 2025 · External reference
Industry sponsorship and research outcome
2017 · External reference
Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication
10.1093/annonc/mdy305 · 2018 · External reference
